Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control

Vos, Rimke C.; Avendonk, Mariëlle Jp van; Jansen, Hanneke; Goudswaard, Alexander Nicolaas N; Donk, Maureen van den; Gorter, Kees J.; Kerssen, Anneloes; Rutten, Guy E.H.M.

doi:10.1002/14651858.cd006992.pub2

Cited by 37 publications

(42 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, insulin-metformin (−0.9%), insulin-AGIs (−0.4%), and insulin-DPP4I (−0.4%) combinations had revealed a less significant change in A1C compared to insulin-SU combination therapy. [ 138 ] Furthermore, a meta-analysis comprising 17 RCTs reported a significantly lower A1C in SU groups (in combination with insulin) compared with placebo (0.46% lower; 95% CI: 0.24, 0.69, I 2 = 43.6%). [ 60 ] Moreover, another meta-analysis also found favorable outcomes with insulin-SU combination therapy in terms of glycemic control compared to insulin monotherapy ( P < 0.0001).…”

Section: S Ulfonylureas and C Ombinationmentioning

confidence: 99%

“…The combination of insulin and SU results in a reduction of necessary insulin dose per day. [ 60 138 ] However, most studies adding SUs to insulin reported milder hypoglycemic episodes versus insulin monotherapy (range: 2.2–6.1 vs. 2.0–2.6 episodes per participant). [ 138 ] The addition of SUs into insulin monotherapy resulted in an additional weight gain of 0.4 to 1.9 kg versus −0.8 to 2.1 kg in the insulin monotherapy group.…”

Section: S Ulfonylureas and C Ombinationmentioning

confidence: 99%

See 1 more Smart Citation

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force

Kalra

Bahendeka

Sahay

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose-lowering drugs.

show abstract

Section: S Ulfonylureas and C Ombinationmentioning

confidence: 99%

Section: S Ulfonylureas and C Ombinationmentioning

confidence: 99%

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force

Kalra

Bahendeka

Sahay

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…In the absence of a clear advantage in respect to glycaemic control, the selection would depend on the cost, side effect profile and patient preferences. The addition of any oral glucose-lowering agents in people with type 2 diabetes mellitus and inadequate glycaemic control despite being on insulin therapy, has positive effects on glycaemic control and insulin requirements [24].…”

Section: Place Of Newer Antidiabetics In Therapymentioning

confidence: 99%

Update on newer antidiabetic drugs in clinical practice

Wanigatunge

2018

J. Postgrad. Inst. Med.

View full text Add to dashboard Cite

“…[ 3 ] finally, insulin should be taken when the islet function is severely damaged. [ 3 ] However, both the last 2 treatments will lead to many side effects, such as hypoglycemia, nausea and vomiting, [ 6 ] which will seriously affect the life quality of patients.…”

Section: Introductionmentioning

confidence: 99%

Large dosage Huangqin (Scutellaria) and Huanglian (Rhizoma Coptidis) for T2DM

et al. 2020

View full text Add to dashboard Cite

Introduction: Type 2 diabetes mellitus (T2DM) is a metabolic disease with widespread concern in the world. It has the characteristics of high incidence rate and high disability rate, which seriously affects economic and social development. large dose herb Rhizoma Coptidis (Huanglian) and Scutellaria (Huangqin) or compound prescription contain large dose Huanglian and Huanglian for treatment of T2DM has already been confirmed. However, due to the lack of evidence, there is no specific method or suggestion, so it is necessary to carry out systematic evaluation on Coptidis and Scutellaria and provide effective evidence for further research. Methods and analysis: The following databases will be searched from their inception to June 2020: Electronic database includes PubMed, Embase, Cochrane Library, Web of Science, Nature, Science online, Chinese Biomedical Database WanFang, VIP medicine information, and China National Knowledge Infrastructure. Primary outcomes: fasting blood-glucose (FBG), 2 Hours Postprandial Blood Glucose (2hPBG), Glycosylated hemoglobin A1c (HbA1c). additional outcomes: Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), triglycerides (TG), total serum cholesterol (TC). Data will be extracted by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. Results: The results of this study will systematically evaluate the effectiveness and safety of large dose Huanglian and Huangqin intervention for people with T2DM. Conclusion: The systematic review of this study will summarize the current published evidence of large dose Huanglian and Huangqin for the treatment of T2DM, which can further guide the promotion and application of it. Ethics and dissemination: This study is a systematic review, the outcomes are based on the published evidence, so examination and agreement by the ethics committee are not required in this study. We intend to publish the study results in a journal or conference presentations. Open Science Framework (OSF) registration number: July 21, 2020. osf.io/b6r3z. ( https://osf.io/b6r3z )

show abstract

Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control

Cited by 37 publications

References 158 publications

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force

Update on newer antidiabetic drugs in clinical practice

Large dosage Huangqin (Scutellaria) and Huanglian (Rhizoma Coptidis) for T2DM

Contact Info

Product

Resources

About